Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
00002-7640-01 00002-7640 Pemetrexed disodium Alimta 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan. 15, 2008 In Use
50242-0145-01 50242-0145 Pertuzumab Perjeta 30.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 8, 2012 In Use
76128-0155-75 76128-0155 Porfimer sodium Photofrin 75.0 mg/31.8mL Chemotherapy Photosensitizing Agent Cytotoxin Intravenous Dec. 27, 1995 In Use
00069-4541-01 00069-4541 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous May 28, 2011 Aug. 31, 2015 No Longer Used
00069-4541-02 00069-4541 Dexamethasone Sodium Phosphate Dexamethasone Sodium Phosphate 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous May 11, 2011 Aug. 31, 2015 No Longer Used
00409-3217-05 00409-3217 Methylprednisolone Sodium Succinate A-Methapred 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Oct. 6, 2006 July 1, 2010 No Longer Used
00409-3217-15 00409-3217 Methylprednisolone Sodium Succinate A-Methapred 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Oct. 6, 2006 July 1, 2010 No Longer Used
00143-9554-01 00143-9554 Leucovorin Calcium Leucovorin Calcium 100.0 mg/10mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous March 28, 1988 In Use
00143-9555-01 00143-9555 Leucovorin Calcium Leucovorin Calcium 50.0 mg/5mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Sept. 14, 1987 In Use
00143-9558-01 00143-9558 Levoleucovorin Levoleucovorin 50.0 mg/5mL Ancillary Therapy Chemoprotective Antidote Intravenous July 7, 2016 In Use
70121-1099-01 70121-1099 Levoleucovorin Levoleucovorin 50.0 mg/1 Ancillary Therapy Chemoprotective Antidote Intravenous Feb. 13, 2017 In Use
00338-1305-01 00338-1305 Mesna Mesnex 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 30, 1988 In Use
00338-1305-03 00338-1305 Mesna Mesnex 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Dec. 30, 1988 In Use
00069-0107-01 00069-0107 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 10, 2011 Dec. 31, 2017 No Longer Used
00069-0109-01 00069-0109 Pamidronate Disodium Pamidronate Disodium 9.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 10, 2011 Dec. 31, 2017 No Longer Used
00069-0186-01 00069-0186 Pamidronate Disodium Pamidronate Disodium 3.0 mg/mL Ancillary Therapy Bisphosphonate Intravenous May 10, 2011 Dec. 31, 2017 No Longer Used
00641-6079-01 00641-6079 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 In Use
00069-1340-02 00069-1340 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous May 10, 2011 July 31, 2014 No Longer Used
00069-1340-05 00069-1340 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous May 10, 2011 May 31, 2014 No Longer Used
00069-1340-16 00069-1340 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous May 10, 2011 May 31, 2014 No Longer Used
73042-0201-01 73042-0201 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Nov. 25, 2020 In Use
74527-0022-02 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan. 15, 2021 In Use
74527-0022-03 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan. 15, 2021 In Use
00069-0238-01 00069-0238 Rituximab-pvvr Ruxience 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 23, 2020 In Use
00069-0249-01 00069-0249 Rituximab-pvvr Ruxience 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 23, 2020 In Use
00069-0315-01 00069-0315 Bevacizumab-bvzr Zirabev 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
00069-0342-01 00069-0342 Bevacizumab-bvzr Zirabev 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
00703-3216-01 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 25, 2020 In Use
00703-3216-81 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3217-01 00703-3217 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3213-01 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3213-81 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3218-01 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3218-81 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00338-0067-01 00338-0067 doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline INTRAVITREAL, Intravenous Aug. 13, 2019 In Use
00338-0063-01 00338-0063 doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 13, 2019 In Use
73462-0101-01 73462-0101 Trilaciclib Cosela 300.0 mg/20mL Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Intravenous Feb. 12, 2021 In Use
00069-0308-01 00069-0308 trastuzumab-qyyp Trazimera 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous March 10, 2021 In Use
00338-0080-01 00338-0080 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 15, 2019 In Use
00338-0086-01 00338-0086 Doxorubicin Hydrochloride Liposome Doxorubicin Hydrochloride Liposome 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 15, 2019 In Use
00703-3071-01 00703-3071 Romidepsin Romidepsin 5.0 mg/mL Chemotherapy Enzyme Inhibitor HDAC Intravenous April 14, 2020 In Use
00703-4004-01 00703-4004 Romidepsin Romidepsin 5.0 mg/mL Chemotherapy Enzyme Inhibitor HDAC Intravenous April 14, 2020 In Use
16714-0137-01 16714-0137 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 25, 2021 In Use
16729-0351-92 16729-0351 busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous July 22, 2019 In Use
39822-2100-02 39822-2100 dactinomycin dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous July 31, 2019 In Use
00591-4385-79 00591-4385 fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 19, 2019 In Use
16714-0120-01 16714-0120 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 16, 2020 In Use
16714-0929-01 16714-0929 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 20, 2020 In Use
00143-9384-01 00143-9384 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 8, 2020 In Use
00338-0008-01 00338-0008 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
50242-0051-10 50242-0051 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous June 3, 2019 In Use
50242-0051-21 50242-0051 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov. 26, 1997 In Use
50242-0103-01 50242-0103 polatuzumab vedotin POLIVY 30.0 mg/1.88mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Sept. 18, 2020 In Use
50242-0132-01 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb. 10, 2017 In Use
50242-0132-10 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous June 3, 2019 In Use
50242-0917-01 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous May 18, 2016 In Use
50242-0917-86 50242-0917 Atezolizumab Tecentriq 1200.0 mg/20mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous Aug. 11, 2016 In Use
16714-0001-01 16714-0001 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous March 22, 2021 In Use
43598-0859-11 43598-0859 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 6, 2019 In Use
43598-0948-11 43598-0948 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous July 1, 2020 In Use
51662-1483-01 51662-1483 SOLU-MEDROL(R) METHYLPREDNISOLONE SODIUM SUCCINAT SOLU-MEDROL(R) METHYLPREDNISOLONE SODIUM SUCCINAT 500.0 mg/4mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Dec. 14, 2019 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 28, 2019 In Use
55513-0224-01 55513-0224 rituximab-arrx Riabni 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0326-01 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
68001-0480-22 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68001-0480-35 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68083-0381-01 68083-0381 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
70700-0169-22 70700-0169 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
42658-0019-01 42658-0019 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 20, 2020 In Use
43598-0389-57 43598-0389 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous April 22, 2019 In Use
47335-0323-40 47335-0323 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
47335-0895-40 47335-0895 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
47335-0939-40 47335-0939 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
49315-0007-10 49315-0007 Arsenic trioxide Arsenic trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Sept. 3, 2019 In Use
49315-0008-03 49315-0008 Doxorubicin hydrochloride DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 14, 2020 In Use
49315-0009-07 49315-0009 Doxorubicin hydrochloride DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 14, 2020 In Use
50742-0430-01 50742-0430 decitabine DECITABINE 50.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Sept. 25, 2019 In Use
55150-0386-01 55150-0386 CARBOPLATIN CARBOPLATIN 600.0 mg/60mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 3, 2020 In Use
60505-6132-06 60505-6132 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 4, 2017 In Use
60505-6132-07 60505-6132 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 4, 2017 In Use
60505-6132-08 60505-6132 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 5, 2020 In Use
63323-0825-20 63323-0825 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 2, 2019 In Use
63759-3028-01 63759-3028 gemcitabine GEMCITABINE 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
63759-3029-01 63759-3029 gemcitabine GEMCITABINE 1.0 g/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
72485-0213-15 72485-0213 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Sept. 4, 2020 In Use
68083-0382-01 68083-0382 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
70700-0170-22 70700-0170 Irinotecan hydrochloride Irinotecan hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
68083-0259-01 68083-0259 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 10, 2019 In Use
68001-0389-36 68001-0389 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
68001-0390-77 68001-0390 Mitomycin Mitomycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
68001-0391-79 68001-0391 Mitomycin Mitomycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 14, 2019 In Use
67184-0501-01 67184-0501 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 11, 2016 In Use
67184-0502-01 67184-0502 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 11, 2016 In Use
68001-0468-36 68001-0468 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 9, 2020 In Use
68001-0468-37 68001-0468 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Dec. 9, 2020 In Use
65219-0200-05 65219-0200 Temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Nov. 20, 2020 In Use
68083-0202-01 68083-0202 Temsirolimus Injection Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Aug. 26, 2019 In Use
16729-0295-12 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Oct. 3, 2017 In Use
16729-0295-31 16729-0295 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound INTRACAVERNOUS, Intravenous Sept. 19, 2017 In Use

Found 10,000 results in 7 milliseconds — Export these results